Enhanced Oral Bioavailability of Celecoxib Nanocrystalline Solid Dispersion based on Wet Media Milling Technique: Formulation, Optimization and In Vitro/In Vivo Evaluation.
bioavailability
celecoxib
experimental design
lyophilization
nanocrystal
wet media milling
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
11 Jul 2019
11 Jul 2019
Historique:
received:
17
06
2019
revised:
05
07
2019
accepted:
05
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Celecoxib (CLX), a selective COX-2 inhibitor, is a biopharmaceutics classification system (BCS) class II drug with its bioavailability being limited by thepoor aqueoussolubility. The purpose of this study was to develop and optimize CLX nanocrystalline(CLX-NC) solid dispersion prepared by the wet medium millingtechnique combined with lyophilizationto enhance oral bioavailability. In formulation screening, the resulting CLX-NC usingpolyvinylpyrrolidone (PVP) VA64 and sodiumdodecyl sulfate (SDS) as combined stabilizers showed the minimum particle size and a satisfactory stability. The formulation and preparation processwere further optimized by central composite experimentaldesign with PVP VA64 concentration (X
Identifiants
pubmed: 31336734
pii: pharmaceutics11070328
doi: 10.3390/pharmaceutics11070328
pmc: PMC6680726
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science and Technology Major Project
ID : 2017ZX09201-003
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2017BH065
Organisme : Open Project of Shandong Collaborative Innovation Center for Antibody Drugs
ID : CIC-AD1841
Organisme : Doctoral Starting up Foundation of Liaocheng University
ID : 318051634
Organisme : Taishan Scholar Foundation of Shandong Province
ID : 2019
Références
Eur J Pharm Biopharm. 2004 Mar;57(2):263-7
pubmed: 15018983
J Pharm Pharmacol. 2004 Jul;56(7):827-40
pubmed: 15233860
Nat Rev Drug Discov. 2004 Sep;3(9):785-96
pubmed: 15340388
Toxicol Pathol. 2008 Jan;36(1):43-8
pubmed: 18337220
Int J Nanomedicine. 2008;3(3):295-309
pubmed: 18990939
J Chem Phys. 2008 Oct 21;129(15):154116
pubmed: 19045185
Curr Drug Metab. 2010 Feb;11(2):197-207
pubmed: 20384585
Int J Pharm. 2010 Oct 31;399(1-2):129-39
pubmed: 20674732
J Pharm Pharmacol. 2010 Nov;62(11):1569-79
pubmed: 21039542
J Pharm Pharmacol. 2010 Nov;62(11):1580-90
pubmed: 21072971
Int J Pharm. 2013 Aug 30;453(1):142-56
pubmed: 23000841
J Control Release. 2013 Dec 28;172(3):1126-41
pubmed: 23954372
Molecules. 2014 Dec 04;19(12):20325-39
pubmed: 25486246
Int J Pharm. 2015 Jan 30;478(2):540-52
pubmed: 25490182
J Control Release. 2015 Aug 10;211:85-93
pubmed: 26054795
Pharmaceutics. 2016 May 20;8(2):null
pubmed: 27213434
J Control Release. 2017 Jun 28;256:9-18
pubmed: 28414149
Eur J Pharm Sci. 2017 Jun 15;104:356-365
pubmed: 28435075
Carbohydr Polym. 2018 Feb 1;181:570-578
pubmed: 29254009
Int J Pharm. 2018 Feb 15;537(1-2):73-83
pubmed: 29262301
Drug Discov Today. 2018 Mar;23(3):534-547
pubmed: 29326082
Int J Pharm. 2018 Apr 5;540(1-2):89-97
pubmed: 29371019
Int J Pharm. 2018 Apr 5;540(1-2):150-161
pubmed: 29438724
Colloids Surf B Biointerfaces. 2018 Dec 1;172:118-126
pubmed: 30144623
Pharmazie. 2018 Sep 1;73(9):498-502
pubmed: 30223931
Eur J Pharm Sci. 2019 Jan 15;127:60-70
pubmed: 30343153
Pharmaceutics. 2019 Mar 20;11(3):null
pubmed: 30897776